Physician profile
Jane Reusch
NPI 1487673000
$58,681.71
in general payments reported to CMS, 2019-2025
6 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $4,050 · 2021: $8,934 · 2022: $13K · 2023: $7,817 · 2024: $7,375 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $1,504 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,238 · Food and Beverage: $633 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,050.00 |
| Travel and Lodging | $1,503.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,237.50 |
| Food and Beverage | $632.60 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $38,059.08 | 2021-2025 | Minimed 780g, Minimed 770g |
| Medtronic Minimed, INC. | $11,591.09 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $8,778.91 | 2019 | |
| Esperion Therapeutics, INC. | $130.65 | 2021 | |
| Novo Nordisk INC | $121.98 | 2023-2025 | Ozempic |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Reusch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.